Compare LASR & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASR | AMLX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 2018 | 2021 |
| Metric | LASR | AMLX |
|---|---|---|
| Price | $37.11 | $29.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $82.13 | $43.00 |
| AVG Volume (30 Days) | 806.4K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.99 | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | $191,359,000.00 | ★ $380,786,000.00 |
| Revenue This Year | $17.05 | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 38.09 | ★ 1612.94 |
| 52 Week Low | $28.05 | $10.83 |
| 52 Week High | $86.95 | $41.14 |
| Indicator | LASR | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 52.46 |
| Support Level | N/A | $12.97 |
| Resistance Level | $41.42 | $34.35 |
| Average True Range (ATR) | 1.77 | 1.21 |
| MACD | 0.07 | 0.17 |
| Stochastic Oscillator | 47.74 | 86.35 |
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.